Global Primary Biliary Cholangitis Market – Industry Trends and Forecast to 2029

Market Analysis and Size

Primary biliary cirrhosis is a chronic liver disease that produces inflammation, fibrosis, and bile duct obstruction, resulting in the loss of tiny bile ducts within the liver. Autoimmunity, infection, and/or genetic predisposition are all possible causes of primary biliary cirrhosis. Itching, osteoporosis, high blood cholesterol, and malabsorption of fat and fat-soluble vitamins are symptoms of primary biliary cirrhosis, which can progress to hepatomegaly and hyperpigmentation splenomegaly, jaundice, sicca syndrome, or Kayser-Fleischer rings. Primary biliary cirrhosis develops over time and might eventually lead the liver to stop functioning completely.

Data Bridge Market Research analyses that the primary biliary cholangitis market was valued at USD 784.81 million in 2021 and is expected to reach USD 1,744.47 million by 2029, registering a CAGR of 10.50% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Primary biliary cholangitis, also known as primary biliary cirrhosis, is a chronic liver condition in which the bile ducts are gradually damaged. PBC has no known treatment. To control symptoms and reduce the progression of PBC, doctors prescribe medication. Ursodiol aids in the removal of bile from the liver. In many cases, this medication improves liver function and slows the course of liver disease. If ursodeoxycholic acid (UDCA) is ineffective or cannot be tolerated, obeticholic acid is used alone or in combination with it. This treatment lowers bile production while increasing bile flow out of the liver. Other pharmacological choices are available depending on the individual circumstances of each patient and the existence of other medical disorders. If liver function continues to deteriorate after medical treatment, a liver transplant may be required.

Primary Biliary Cholangitis Market Dynamics

Drivers

• Increasing prevalence of primary biliary cholangitis

The rising prevalence of primary biliary cholangitis across the globe is estimated to enhance the market's growth. Primary biliary cholangitis (PBC) is an uncommon disease that causes a persistent, progressive liver disorder. It primarily affects women and usually strikes between the ages of 30 and 60.  The tiny bile duct in the liver is usually affected by PBC. Primary biliary cholangitis is split into four phases: stage 1 (no scarring) to stage 4 (cirrhosis). A mix of causes, including autoimmune, genetic, and environmental factors, can cause PBC.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of primary biliary cholangitis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the primary biliary cholangitis market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and addiction of smoking will result in the expansion of primary biliary cholangitis market. Rising level of disposable income and surging geriatric population are the major factors anticipated to flourish the market’s growth rate during the forecast period of 2022-2029.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the primary biliary cholangitis market growth. The primary biliary cholangitis treatment market is anticipated to grow because to an increase in pipeline research to discover prominent medicines for rare diseases such as primary biliary cholangitis. For instance, CymaBay Therapeutics, Inc. started a placebo-controlled, randomised phase 3 clinical trial for seladelpar 5-10mg in October 2018. The researchers wanted to see if seladelpar was safe and effective in individuals with primary biliary cholangitis (PBC) and if there was an inadequate response or intolerance to ursodeoxycholic acid (UDCA). The research was expected to be finished in December 2021. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the primary biliary cholangitis market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the primary biliary cholangitis market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This primary biliary cholangitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the primary biliary cholangitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Primary biliary cholangitis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Recent Development

• In May 2022, Intercept Pharmaceuticals, Inc. announced that the first patient has been dosed in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF) for treating patients suffering from primary biliary cholangitis (PBC) who have not achieved an adequate biochemical response to ursodeoxycholic acid.

Global Primary Biliary Cholangitis Market Scope

The primary biliary cholangitis market is segmented on the basis of treatment type, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Liver Transplantation
• Drug Therapy
• Ursodeoxycholic acid (UDCA)
• Obeticholic acid
• Fibrates
• Budesonide
• Others

Diagnosis

• Imaging Tests
• Magnetic resonance elastography (MRE)
• Magnetic resonance cholangiopancreatography (MRCP)
• Ultrasound
• FibroScan
• Blood Tests
• Cholesterol test
• Antibody tests
• Liver tests
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Primary Biliary Cholangitis Market Regional Analysis/Insights

The primary biliary cholangitis market is analyzed and market size insights and trends are provided by country, treatment type, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the primary biliary cholangitis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the primary biliary cholangitis market because of the rising prevalence of primary biliary cholangitis and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and the presence of major key players will further propel the market’s growth rate.

Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to increasing number of geriatric population and surging level of disposable income in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Primary Biliary Cholangitis Market Share Analysis

The primary biliary cholangitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to primary biliary cholangitis market.

Some of the major players operating in the primary biliary cholangitis market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Bayer AG (Germany)
• Boehringer Ingelheim International GmbH. (Germany)
• Dr. Reddy’s Laboratories Ltd. (India)
• Gilead Sciences, Inc. (U.S.)
• Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• AbbVie Inc. (U.S.)
• Lupin (India)
• Allergan (Ireland)

SKU-53498